Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced the adoption of its Blood Volume Analysis (BVA) technology by three new hospitals. The expansion includes both the company's CLIA-certified ezBVA Lab service and on-site blood volume analyzers.
The new facilities include a Tennessee medical center adopting ezBVA Lab services for cardiology, a major Arkansas hospital implementing an on-site analyzer, and a leading referral hospital serving Arizona, Nevada, and Utah utilizing the ezBVA Lab service for heart failure patients. The company expects continued sales growth throughout 2025 as clinicians increasingly recognize BVA's benefits for optimizing fluid management.
Daxor Corporation (Nasdaq: DXR), leader mondiale nella tecnologia per la misurazione del volume ematico, ha annunciato l'adozione della sua tecnologia Blood Volume Analysis (BVA) da parte di tre nuovi ospedali. L'espansione comprende sia il servizio ezBVA Lab certificato CLIA dell'azienda, sia gli analizzatori di volume ematico in loco.
Le nuove strutture includono un centro medico del Tennessee che utilizza i servizi ezBVA Lab per la cardiologia, un importante ospedale dell'Arkansas che ha implementato un analizzatore in loco, e un ospedale di riferimento leader che serve Arizona, Nevada e Utah, impiegando il servizio ezBVA Lab per pazienti con insufficienza cardiaca. L'azienda prevede una crescita continua delle vendite nel 2025, grazie al crescente riconoscimento da parte dei medici dei vantaggi della BVA per ottimizzare la gestione dei fluidi.
Daxor Corporation (Nasdaq: DXR), líder mundial en tecnología de medición del volumen sanguíneo, ha anunciado la adopción de su tecnología Blood Volume Analysis (BVA) por parte de tres nuevos hospitales. La expansión incluye tanto el servicio ezBVA Lab certificado por CLIA de la empresa como los analizadores de volumen sanguíneo en sitio.
Las nuevas instalaciones incluyen un centro médico en Tennessee que adopta los servicios ezBVA Lab para cardiología, un hospital importante en Arkansas que implementa un analizador en sitio, y un hospital de referencia líder que atiende a Arizona, Nevada y Utah, utilizando el servicio ezBVA Lab para pacientes con insuficiencia cardíaca. La compañía espera un crecimiento continuo en ventas durante 2025 a medida que los clínicos reconocen cada vez más los beneficios de BVA para optimizar la gestión de líquidos.
Daxor Corporation (나스닥: DXR)는 혈액량 측정 기술 분야의 세계적인 선두주자로서, 세 개의 신규 병원에서 자사의 혈액량 분석(BVA) 기술을 도입했다고 발표했습니다. 이번 확장에는 회사의 CLIA 인증 ezBVA 연구소 서비스와 현장 혈액량 분석기가 포함됩니다.
신규 시설에는 심장학을 위한 ezBVA 연구소 서비스를 도입한 테네시 의료 센터, 현장 분석기를 도입한 아칸소의 주요 병원, 그리고 심부전 환자를 위한 ezBVA 연구소 서비스를 활용하는 애리조나, 네바다, 유타 지역의 선도적인 의뢰 병원이 포함됩니다. 회사는 임상의들이 BVA의 체액 관리 최적화 이점을 점점 더 인식함에 따라 2025년 전반에 걸쳐 판매가 지속적으로 성장할 것으로 기대하고 있습니다.
Daxor Corporation (Nasdaq : DXR), leader mondial de la technologie de mesure du volume sanguin, a annoncé l’adoption de sa technologie Blood Volume Analysis (BVA) par trois nouveaux hôpitaux. Cette expansion comprend à la fois le service ezBVA Lab certifié CLIA de l’entreprise et des analyseurs de volume sanguin sur site.
Les nouvelles installations comprennent un centre médical du Tennessee adoptant les services ezBVA Lab pour la cardiologie, un hôpital majeur de l’Arkansas mettant en place un analyseur sur site, et un hôpital de référence de premier plan desservant l’Arizona, le Nevada et l’Utah, utilisant le service ezBVA Lab pour les patients atteints d’insuffisance cardiaque. L’entreprise prévoit une croissance continue des ventes tout au long de 2025, les cliniciens reconnaissant de plus en plus les avantages de la BVA pour optimiser la gestion des fluides.
Daxor Corporation (Nasdaq: DXR), der weltweit führende Anbieter von Blutvolumenmessungstechnologie, hat die Einführung seiner Blood Volume Analysis (BVA)-Technologie durch drei neue Krankenhäuser bekannt gegeben. Die Erweiterung umfasst sowohl den CLIA-zertifizierten ezBVA Lab-Service des Unternehmens als auch vor Ort eingesetzte Blutvolumenanalysatoren.
Zu den neuen Einrichtungen zählen ein Medizinisches Zentrum in Tennessee, das ezBVA Lab-Dienste für die Kardiologie einsetzt, ein bedeutendes Krankenhaus in Arkansas, das einen vor Ort installierten Analysator verwendet, sowie ein führendes Überweisungszentrum, das Arizona, Nevada und Utah versorgt und den ezBVA Lab-Service für Herzinsuffizienzpatienten nutzt. Das Unternehmen erwartet für 2025 ein anhaltendes Umsatzwachstum, da Kliniker zunehmend die Vorteile der BVA zur Optimierung des Flüssigkeitsmanagements erkennen.
- Expansion into three new prestigious healthcare facilities
- Dual revenue streams from both ezBVA Lab services and on-site analyzers
- Growing market penetration across multiple U.S. regions
- Management expects accelerated sales growth throughout 2025
- None.
Insights
Daxor's expansion into three new hospitals signals growing market acceptance and revenue growth potential for its blood volume analysis technology.
Daxor Corporation's expansion into three new hospitals represents a significant commercial milestone for its blood volume analysis (BVA) technology. The company is penetrating the market through dual deployment strategies: their CLIA-certified ezBVA Lab service providing next-day results and on-site blood volume analyzers at healthcare facilities.
The three new adoptions span different geographic regions (Tennessee, Arkansas, and a multi-state serving facility for Arizona, Nevada, and Utah), indicating broad regional acceptance rather than just localized success. Each implementation targets both inpatient and outpatient cardiology applications, particularly focusing on heart failure management - a high-cost, high-mortality condition where precise fluid management is critical.
This expansion carries particular significance in the medical device sector where adoption cycles are typically lengthy and require substantial clinical validation. That Daxor is securing placements across both community and major referral hospitals suggests the technology is gaining traction across different tiers of the healthcare system.
The dual-deployment approach (ezBVA Lab service and on-site analyzers) represents a flexible business model that can accommodate different hospital needs and budgets, potentially accelerating adoption. The technology addresses the critical clinical challenge of fluid management in heart failure patients, where both over and under-treatment lead to adverse outcomes and increased costs.
While specific financial projections aren't provided, the announcement's timing and the management's expectation of "accelerated sales growth" throughout 2025 suggests positive revenue momentum that may translate to improved financial performance in upcoming quarters.
Continued Integration of Daxor’s ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook
Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology into three new hospitals, a testament to the growing recognition of BVA's essential role in improving lives and reducing healthcare costs. This growth is driven by a combination of Daxor's state-of-the-art CLIA-certified ezBVA Lab service, which delivers on-demand, next-day blood volume analysis results, and an on-site placement of its blood volume analyzer. The company expects accelerated sales growth to continue throughout 2025 as clinicians increasingly embrace the benefits of BVA for optimizing fluid management decisions.
Recent sales wins include:
- Expansion into a key Tennessee medical center within a large integrated community healthcare system in the Appalachian Highlands, is adopting ezBVA Lab services for inpatient and outpatient cardiology applications
- A major hospital serving Arkansas is integrating BVA with an on-site analyzer to enhance its advanced heart care programs for both inpatient and outpatient settings
- A leading referral hospital serving Arizona, Nevada and Utah is utilizing Daxor’s ezBVA Lab service for its advanced heart failure patients, both inpatient and outpatient
“We are incredibly proud to announce the expansion of our BVA technology into three renowned facilities as a testament to the growing recognition of BVA's pivotal role in improving lives and reducing healthcare costs,” said Michael Feldschuh, Daxor Corporation CEO and President. “This momentum, driven by the increasing integration of our ezBVA Lab Service and on-site analyzers, underscores our commitment to providing clinicians, regardless of location, with precise tools to guide optimal fluid management.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What new facilities has Daxor (DXR) added for its Blood Volume Analysis technology in 2025?
How does Daxor's (DXR) Blood Volume Analysis technology generate revenue?
What is the expected growth outlook for Daxor (DXR) in 2025?
What applications are hospitals using Daxor's (DXR) BVA technology for?
